

73. Lauralee Miller, Murray, Utah, Court of Federal Claims No: 22–1903V
74. Ciena Westrich, Phoenix, Arizona, Court of Federal Claims No: 22–1906V
75. Randy Ritchie, Savannah, Georgia, Court of Federal Claims No: 22–1907V
76. Lisa Snell on behalf of K. W., Phoenix, Arizona, Court of Federal Claims No: 22–1909V
77. Suzanne Meeley, Drexel Hill, Pennsylvania, Court of Federal Claims No: 22–1911V
78. Gonzalo Lopez and Rosalia Lopez on behalf of A. L., Phoenix, Arizona, Court of Federal Claims No: 22–1912V
79. Chelsea Hughes, Olney, Maryland, Court of Federal Claims No: 22–1917V
80. Tiffany Taylor on behalf of C. T., Stanford, Kentucky, Court of Federal Claims No: 22–1918V
81. Aidan Walsh, Boston, Massachusetts, Court of Federal Claims No: 22–1919V
82. Aubrielle Smythe, Huntsville, Alabama, Court of Federal Claims No: 22–1920V
83. Sakinah Wood, Atlanta, Georgia, Court of Federal Claims No: 22–1924V
84. Alexander Kurk, St. Petersburg, Florida, Court of Federal Claims No: 22–1930V
85. Joseph Pilcher, Los Angeles, California, Court of Federal Claims No: 22–1931V
86. John D. Sherwood, Lexington, Ohio, Court of Federal Claims No: 22–1934V
87. Lorraine Martin, Port Orange, Florida, Court of Federal Claims No: 22–1936V
88. Lorraine Martin, Port Orange, Florida, Court of Federal Claims No: 22–1937V
89. Anwesa Paul, Westfield, New Jersey, Court of Federal Claims No: 22–1938V
90. Danielle Spiller, Manalapan, New Jersey, Court of Federal Claims No: 22–1939V
91. Elizabeth Cimino, Phoenix, Arizona, Court of Federal Claims No: 22–1940V
92. Prisca Thomas, Beverly Hills, California, Court of Federal Claims No: 22–1941V

[FR Doc. 2023–03184 Filed 2–14–23; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2).

Date: March 2–3, 2023.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland 20892 (Virtual Meeting).

Contact Person: Nina Sidorova, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, MSC 6200, Room 3AN18–01, Bethesda, Maryland 20892, 301–594–3663, sidorova@nigms.nih.gov.

Information is also available on the Institute's/Center's home page: www.nigms.nih.gov/, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: February 9, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–03174 Filed 2–14–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; George M. O'Brien Kidney Consortium Review.

Date: March 29–31, 2023.

Time: 10:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate cooperative agreement applications.

Place: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ann A. Jerkins, Ph.D., Scientific Review Officer, NIDDK/Scientific Review Branch, National Institutes of Health, 6707 Democracy Blvd., Room 7013, Bethesda, MD 20892, 301–594–2242, jerkinsa@nidk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: February 9, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–03175 Filed 2–14–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as